In a phase 2b clinical trial, Beckley Psytech has started treating the first subject for BPL-003, an intranasal synthetic formulation of the psychedelic chemical 5-MeO-DMT intended for patients with treatment-resistant depression. With FDA clearance for investigational new medication status in February, this groundbreaking research represents the biggest controlled examination into the potential of 5-MeO-DMT, involving 40 locations throughout Australia, Europe, and the US.
Save dough on the good-good without breaking a sweat. The post Why you should shop…
Quantity vs. Frequency - One of the most significant distinctions between medical and recreational cannabis…
At least 10 states and Amsterdam have new stores for you. The post Grand Openings:…
Welcome all Stargazers! November promises a month of celestial buoyancy even as the days and…
According to fresh data from the US National Institute on Drug Abuse, young women have…
Many states have enacted strict privacy laws that prevent dispensaries from sharing customer data without…